This week in therapeutics




Licensing status

Publication and contact information



Sphingosine 1-phosphate (S1P); S1P receptor 1 (S1PR1; S1P1; EDG1)


Cell culture and mouse studies suggest inhibiting S1P-S1PR1 signaling could help treat rhabdomyosarcoma. In normal mice, radiotherapy or chemotherapy increased S1P levels in multiple tissues. In multiple human rhabdomyosarcoma cell lines, S1P bound to S1PR1 and led to increased migration and adhesion compared with vehicle. In mice pretreated with radiotherapy and engrafted with human rhabdomyosarcoma cells, the anti-S1P l-aptamer NOX-S93 decreased the number of metastases compared with no treatment. Ongoing work includes testing the aptamer in rhabdomyosarcoma models pretreated with chemotherapy.
Noxxon Pharma AG's spiegelmer NOX-S93 is in preclinical testing to treat undisclosed cancer, ophthalmic and autoimmune indications.

SciBX 6(23); doi:10.1038/scibx.2013.577
Published online June 13, 2013

Patent and licensing status of findings unavailable; NOX-S93 patented by Noxxon Pharma AG; available for licensing

Schneider, G. et al. Mol. Cancer Res.; published online April 24, 2013;
Contact: Mariusz Z. Ratajczak, University of Louisville, Louisville, Ky.